IL28B基因多态性及其表达与慢性乙型肝炎感染转归的相关性研究

Correlation between genetic variation and expression of IL28B with prognoses of chronic hepatitis B infection patients

  • 摘要: 目的 探讨IL28B基因多态性(SNPs)及其血清IFN-λ3水平与聚乙二醇干扰素联合利巴韦林治疗乙型肝炎疗效的相关性。方法 选择2013年6月-2013年12月100例HBeAg阳性慢性乙型肝炎(CHB)患者,给予聚乙二醇化干扰素α(Peg-INF-α)联合利巴韦林规范治疗48周后,分为应答组48例及非应答组52例,分析患者IL28B SNPs、HBV基因型、HBsAg、HBeAg及IFN-λ3表达与患者治疗疗效的关系。结果 IL28B基因rs 12979860 位点CC型和CT+TT型的比例在应答组和非应答组差异较大,差异有统计学意义(χ2=8.253,P<0.05);应答组患者治疗48周后HBV-DNA、HBsAg、HBeAg水平均低于非应答组,差异均有统计学意义(P<0.05);应答组患者血清IFN-λ3水平高于非应答组, 差异有统计学意义(P<0.05);在应答组及非应答组中, IL28B基因CC型患者48周IFN-λ3血清学表达水平高于CT+TT型,差异均有统计学意义(P<0.05)。<目的 IL28BSNPs及其血清IFN-λ3水平可能影响Peg-INF-α联合利巴韦林治疗的应答反应,对CHB患者治疗疗效有一定预测价值。

     

    Abstract: OBJECTIVE To explore the relationship between the single nucleotide polymorphisms (SNPs) of IL28B gene and the serum levels of IFN-λ3 with polyethylene glycol interferon combined with ribavirin treatment to chronic hepatitis B patients. METHODS A total of 100 HBeAg positive patients with chronic hepatitis B in our hospital from Jun. 2013 to Dec. 2013 were selected and treated with peg-interferon α-2a (Peg-INF-α) combined with ribavirin. After 48 weeks of treatment,all the patients were divided into responsive group( n=48) and non-responsive group(n=52).The relationship among IL28B polymorphisms, HBV genotype, hepatitis B s antigen(HBsAg) levels , HBeAg levels,IFN-λ3 levels and the response to the treatment were analyzed. RESULTS The distribution frequencies of IL28B rs 12979860 CC and CT+TT genotypes showed significant differences between the responsive group and nonresponsive group (χ2=8.253,P<0.05). The levels of HBV-DNA、HBsAg and HBeAg for 48 weeks in responsive group were significantly lower than nonresponsive group, and the difference was statistically significant (P<0.05).The levels of IFN-λ3 for 48 weeks in responsive group were significant higher than nonresponsive group (P<0.05). The levels of IFN-λ3 of IL28B polymorphisms CC genotype were significantly higher than CT+TT genotype (P<0.05). CONCLUSION The levels of IL28B SNPs and IFN-λ3 would be possible to influence the response of peg- interferon α-2a combined with ribavirin, which has certain predict value for the treatment in CHB patients.

     

/

返回文章
返回